5-Amino-1MQ: The NNMT Inhibitor With No Human Data

At a Glance

5-Amino-1MQ is the most mechanistically interesting compound in the grey-market fat-loss category, and the cleanest example of a pattern worth naming: a well-validated drug target, a credible molecule, a decade of consistent animal data, and not one human study.

The target is NNMT, an enzyme most clinicians have never had reason to think about. It sits at the junction of two systems that matter enormously in metabolism and ageing: the NAD+ salvage pathway and methyl-group metabolism. NNMT consumes nicotinamide, a NAD+ precursor, and uses S-adenosylmethionine as its methyl donor, producing 1-methylnicotinamide, which is excreted. Fat tissue and liver increase NNMT expression with obesity and diabetes. Knock it down, and mice resist diet-induced obesity [1].

The honest verdict: this is good science with a missing final chapter. The rodent data are consistent across independent papers and multiple endpoints — body weight, fat mass, insulin sensitivity, hepatic steatosis, muscle stem cell function. The molecule is orally available and reaches metabolically active tissue. And a compound with this much preclinical support and no human trial after a decade raises its own question: not whether the biology is real, but why nobody has funded the study that would settle it.

A note on classification: 5-Amino-1MQ is not a peptide. It sits in this library because it is sold, stacked and discussed alongside peptides, and because the questions people ask about it are the same ones.

How it works

Start with the enzyme. Nicotinamide N-methyltransferase transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide (vitamin B3), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. For decades NNMT was regarded as a vitamin B3 clearance enzyme and little more; Pissios’s 2017 review is the paper that reframed it as a metabolic regulator [8].

Two currencies are consumed in that single reaction, and both matter:

• Nicotinamide, which would otherwise be salvaged into NAD+ — the cofactor driving sirtuins, mitochondrial redox reactions and DNA repair. More NNMT activity means less nicotinamide available for NAD+.
• SAM, the cell’s universal methyl donor, used for histone methylation and polyamine synthesis.

Kraus and colleagues (Nature 2014) made the case that this matters physiologically. NNMT was the most strongly reciprocally regulated gene when comparing white adipose tissue from adipose-specific GLUT4-knockout and GLUT4-overexpressing mice. NNMT expression is increased in white adipose tissue and liver of obese and diabetic mice, and knockdown of NNMT in fat and liver protected against diet-induced obesity by augmenting cellular energy expenditure. Mechanistically, NNMT inhibition raised adipose SAM and NAD+, upregulated ornithine decarboxylase and spermidine-spermine N¹-acetyltransferase activity and expression through effects on histone H3K4 methylation, and increased polyamine flux — shown directly by elevated urinary excretion and adipocyte secretion of diacetylspermine. In adipocytes, NNMT inhibition increased oxygen consumption in a polyamine-pathway-dependent manner [1].

That is an unusually complete mechanistic chain for a metabolic target: gene regulation, enzyme activity, metabolite flux and oxygen consumption all lining up.

The drug-discovery step came next. Neelakantan and colleagues (2018) screened methylquinolinium scaffolds and found that analogues with primary amine substitutions — the class 5-Amino-1MQ belongs to — showed high membrane permeability by both passive and active transport, and high selectivity: they did not inhibit related SAM-dependent methyltransferases or enzymes of the NAD+ salvage pathway. In cultured adipocytes the inhibitors reduced intracellular 1-MNA, increased intracellular NAD+ and SAM, and suppressed lipogenesis [2].

Two points of practical significance follow. The compound is cell-permeable and orally active, which is why this is a capsule rather than an injection. And the effect is on fat storage and cellular energetics rather than appetite — in the mouse studies, food intake did not change [2].

What the evidence shows

Human evidence: none

There are no published human trials of 5-Amino-1MQ: no pharmacokinetics, no dose-finding, no efficacy, no safety study. Any human dose circulating online is extrapolated from rodent work or copied from vendor material. This is the most important fact on the page, and it is worth stating plainly because the quality of the animal work makes it easy to forget.

Animal and cell evidence (clearly labelled as such)

The compound itself, in diet-induced obese mice. Babula and colleagues (Diabetes Obes Metab 2024) studied 5A1MQ specifically. It dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia. Liver histology showed attenuated hepatic steatosis and reduced macrophage infiltration, with correspondingly lower liver weight, size and triglyceride content. Circulating ALT, AST and ketone bodies normalised. Subcutaneous dosing produced high systemic exposure and effective distribution into adipose, muscle and liver [7].

The class, in obesity. Neelakantan 2018: a potent NNMT inhibitor given systemically to diet-induced obese mice significantly reduced body weight and white adipose mass, decreased adipocyte size and lowered plasma total cholesterol, without affecting total food intake and without observable adverse effects [2].

Combined with diet. Sampson and colleagues (Sci Rep 2021) combined NNMT inhibition with substituting a lean diet in obese mice. The combination accelerated and improved body weight and fat loss, increased the whole-body lean-mass-to-weight ratio, reduced liver and epididymal white adipose weight, and improved hepatic steatosis relative to the diet change alone — normalising body composition and liver adiposity to the levels of age-matched lean controls, with a distinct adipose metabolomic signature including increased ketogenic amino acid abundance [4]. A companion study characterised the associated microbiome changes [5].

Muscle: the more surprising finding. Neelakantan and colleagues (2019) treated 24-month-old mice with an NNMT inhibitor at 5 and 10 mg/kg after an acute tibialis anterior injury. Muscle stem cell proliferation and subsequent fusion were elevated in treated mice, with improved regenerative capacity on contractile function and fibre cross-sectional area [3]. Dimet-Wiley and colleagues (2024) extended this, reporting that NNMT inhibition mimicked and boosted exercise-mediated improvements in muscle function in aged mice [6]. The rationale is NNMT overexpression in aged skeletal muscle, impaired NAD+ salvage, dysregulated SIRT1 activity and increased muscle stem cell senescence.

Beyond metabolism. NNMT inhibition has since been reported to counteract tubular senescence and fibrosis in early chronic kidney disease in rodents [9] — an indication of how broadly the target is being explored.

How to read this body of work

The strengths are real: multiple endpoints, multiple models, a clear mechanism with metabolite-level confirmation, oral bioavailability, and a muscle finding pointing in the opposite direction to the lean-mass problem that dogs the GLP-1 class. If NNMT inhibition did in humans what it does in mice, it would be a genuinely novel metabolic drug.

The limitations are equally real. Much of this work comes from a small number of connected groups. Diet-induced obese mice are a model that has flattered many compounds that later failed. Mouse NAD+ and methyl-group metabolism differ quantitatively from human. And the step that converts promising rodent pharmacology into a medicine — a first-in-human study — has not been taken.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

On the 50–150 mg figures. These come from commercial protocol sources rather than a dose-finding study, and the honest framing is that they are a convention rather than evidence. The two sources named above agree with each other, which is worth something and is not the same as validation. Allometric scaling from the mouse doses used in the muscle work (5–10 mg/kg) gives very different numbers depending on the method chosen — which is precisely why first-in-human studies exist.

Timing and fasting. Morning dosing on an empty stomach is the convention, the stated rationale being that effects on adipocyte lipogenesis are better expressed away from a fed insulin signal. Plausible, untested.

Cycling. The 8–12 weeks on, 4–6 weeks off convention has no pharmacological basis specific to NNMT inhibition. It is imported from peptide practice generally — see peptide cycling protocols.

Stacks commonly used.

• With NAD+ precursors (NMN, NR) — the most common stack and mechanistically the most coherent: precursors supply the substrate, NNMT inhibition stops it being methylated away. Untested in humans. See the NAD supplement guide.
• With a GLP-1 agonist, increasingly common. Worth being clear-eyed about: the GLP-1 drug has 2,500-person randomised trials and 5-Amino-1MQ has none, so attribution of any result is obvious.
• With resistance training — the stack with the strongest mechanistic story given the muscle stem cell findings [3, 6], and also the one most likely to produce a result regardless of the compound.
• With metformin or berberine (both AMPK-directed): no interaction data, overlapping metabolic territory. See metformin vs berberine.

What people report: what works and what doesn’t

Sources: the animal literature above; protocol compilations at peptidedosingprotocols.com and mypeptidematch.com; and the open community record on r/Peptides and r/Biohackers. Community material shows patterns, not proof; no individual account is treated as evidence.

Reported to work

• Gradual fat loss over 8–12 weeks, generally described as modest — “a few pounds”, “slow recomposition” — rather than dramatic. Notably, people do not typically describe appetite suppression, which is consistent with the mouse data showing unchanged food intake [2].
• Energy, training capacity and recovery. The most consistently positive theme, and the one with a matching mechanism in the muscle stem cell and exercise-mimetic studies [3, 6].
• Convenience: an oral capsule with no injection is a genuine practical advantage in this category.

Mixed or unclear

• Whether fat loss exceeds what the accompanying diet and training would produce. Nearly every positive report includes both, and the modest reported effect size makes this impossible to separate anecdotally.
• Whether the NAD+ precursor stack adds anything. Mechanistically attractive, entirely unquantified in humans.
• Dose-response between 50 mg and 150 mg: reports do not consistently favour higher doses.
• Product identity and purity. 5-Amino-1MQ is a simple small molecule that should be cheap and easy to make correctly, but what is in a capsule sold online is unverified, and capsules are harder to assess than lyophilised vials.

Reported not to work / disappointing

• GLP-1-like weight loss. Expectations set by vendor marketing are routinely not met, and this is the dominant disappointment.
• Rapid results. The reported timescale is months, not weeks.
• Side effects described are mild and non-specific: headache, mild nausea, occasional flushing, insomnia if taken late in the day. Serious adverse events are not a theme in the community record — which is reassuring only weakly, since absence of reported harm in an unmonitored population with no bloodwork is not demonstrated safety.

What a properly designed human trial would need to show: oral bioavailability and suppression of plasma 1-methylnicotinamide as a target-engagement biomarker — which is measurable and would immediately reveal whether the compound does anything at all in people at 100 mg — followed by a 12–24 week randomised trial against placebo with DXA body composition and insulin sensitivity as endpoints. The target-engagement study would be inexpensive. Its absence after a decade is the most informative thing about this compound’s commercial status.

Safety and side effects

What animal studies report. Neelakantan 2018 explicitly noted no observable adverse effects in treated mice [2], and Babula 2024 reported normalisation rather than elevation of liver enzymes in obese mice [7]. The methylquinolinium inhibitors were shown to be selective, sparing related SAM-dependent methyltransferases and NAD+ salvage enzymes [2] — selectivity matters, because broad methyltransferase inhibition would be a serious concern.

What is unknown in humans. Everything: absorption, half-life, metabolism, drug interactions, effects on methyl-group balance and homocysteine, consequences of chronically shifting SAM availability, and effects in pregnancy, renal or hepatic impairment.

Theoretical concerns worth tracking. Raising intracellular SAM alters methylation potential broadly, including histone methylation — the mechanism the Nature paper attributed the polyamine effects to [1]. That is the intended mechanism and a reason for caution over long periods, because epigenetic regulation does not come with a well-characterised safety margin. 1-Methylnicotinamide, the metabolite being suppressed, has its own reported vascular and anti-inflammatory activities, so reducing it is not axiomatically benign. And NNMT is overexpressed in several tumour types, where it is studied as a target rather than a protective factor — the oncology interest is in inhibiting it, but no human data exist either way.

Product risk. Sold as a research chemical or, without a lawful basis, as a dietary supplement. No pharmacopoeial standard, no verified content, and capsules give no visual indication of what they hold. See peptide sourcing.

Legal and regulatory status

United States. Not an approved drug for any indication. 5-Amino-1MQ does not appear in FDA’s 503A category 1 or category 2 listings, nor among the bulk substances reviewed by the Pharmacy Compounding Advisory Committee in 2026 — so it has no compounding pathway at all, which is a different situation from a substance FDA has evaluated and declined. It does not qualify as a dietary ingredient, so products marketed as supplements are mislabelled rather than lawfully sold. The category framework is explained in the FDA 2026 compounding update.

European Union and Germany. No authorisation as a medicinal product and no novel-food authorisation, which means it may not lawfully be sold as a food supplement in the EU.

Sport. A substance with no approval for human therapeutic use falls under WADA category S0: prohibited at all times. See peptides and WADA rules.

How it fits: the NAD+ and metabolic shelf

Where 5-Amino-1MQ sits conceptually is more interesting than where it sits practically. Its mechanism is the complement of NAD+ precursor supplementation: rather than adding more substrate, it stops the cell methylating away what it has. For anyone who has wondered why NMN and NR produce such modest clinical effects despite a compelling rationale, NNMT is one of the better answers — and inhibiting it is the logical next move. The muscle findings sharpen the interest, because an agent that supports muscle stem cell function while reducing fat storage would be the inverse of the body-composition problem that defines the incretin era.

What I would want before taking it seriously as a clinical tool is unglamorous: a human pharmacokinetic study with plasma 1-MNA as the target-engagement readout. Until that exists, 5-Amino-1MQ is a well-supported hypothesis being sold as a product, and the right way to hold it is as a target to follow rather than a protocol to run.

Related Articles

• NAD Supplement Guide: NMN, NR, NADH and Oral NAD+ Precursors Compared — the substrate side of the same pathway.
• MOTS-c Peptide: The Mitochondrial Signal That Reshapes Metabolism — the other AMPK- and NAD+-adjacent compound with strong animal data and thin human data.
• Metformin vs Berberine — what a metabolic agent with real human outcome data looks like.
• Tirzepatide: The Dual GIP/GLP-1 Agonist in Full — the benchmark for pharmacological fat loss.
• Peptide Cycling Protocols: How Long to Run Each Peptide — where the on/off cycling convention comes from.
• Peptide Sourcing: Pharmaceutical-Grade vs Grey Market — the practical problem with capsule products of unverified content.